The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Related Posts
Qualcomm tops estimates for earnings and revenue on strong smartphone demand
Qualcomm reported first-quarter earnings on Wednesday that beat consensus expectations on both the top and bottom line.
Displaced Los Angeles-area residents face spiking rents as authorities warn of price gouging
The wildfires have set off a stampede to find housing, leading some homeowners and property managers to raise rents higher than the 10% allowed in […]
Iran attacks U.S. military base in Qatar with missiles
The Iranian attacks on U.S. forces after American B-2 bombers and cruise missiles struck nuclear sites escalate the conflict and raise fears of a regional […]